Analyst Price Target is $44.60
▲ +83.54% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Avidity Biosciences in the last 3 months. The average price target is $44.60, with a high forecast of $71.00 and a low forecast of $27.00. The average price target represents a 83.54% upside from the last price of $24.30.
Current Consensus is
The current consensus among 5 polled investment analysts is to buy stock in Avidity Biosciences. This Buy consensus rating has held steady for over two years.
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.